GlassScriptPhysician profile
Vera Bernik
NPI 1396159893
$2,355.27
in general payments reported to CMS, 2019-2025
20 companies · $522 in 2025
The $522 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $40.60 · 2023: $119 · 2024: $1,674 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,314.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $466.51 | 2023-2024 | Fanapt, Hetlioz |
| Abbvie INC. | $345.01 | 2023-2025 | |
| Lilly USA, LLC | $206.19 | 2024 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $177.25 | 2024 | Xifaxan |
| Agios Pharmaceuticals, INC. | $137.39 | 2024 | Pyrukynd |
| Novo Nordisk INC | $125.00 | 2024 | |
| Argenx US, INC. | $124.99 | 2025 | Vyvgart |
| Astrazeneca Pharmaceuticals LP | $124.99 | 2025 | Breztri |
| Madrigal Pharmaceuticals | $123.86 | 2024 | Rezdiffra |
| Ardelyx, INC. | $123.37 | 2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $122.70 | 2024 | |
| Amgen INC. | $59.12 | 2024-2025 | Krystexxa, Repatha, Otezla |
| Axsome Therapeutics, INC. | $52.78 | 2025 | Symbravo |
| Boston Scientific Corporation | $34.28 | 2025 | Wavewriter Alpha Prime 16 |
| Aimmune Therapeutics, INC. | $28.54 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $28.18 | 2023 | Intellis Adaptivestim |
| Scilex Pharmaceuticals INC. | $21.85 | 2022 | |
| Avanir Pharmaceuticals, INC. | $18.75 | 2022 | |
| Sumitomo Pharma America, INC. | $17.46 | 2025 | Gemtesa |
| Pfizer INC. | $17.05 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vera Bernik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.